Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Methotrexate resistant cells as targets for selective chemotherapy.

J R Bertino, E Mini, A Sobrero

Advances in Enzyme Regulation

|January 1, 1985

Summary

New strategies target methotrexate-resistant cancer cells by understanding drug resistance mechanisms. Research focuses on developing novel antifolates and prodrugs to overcome resistance, with some agents in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.

British journal of cancer·2024

Same author

Prophylactic mesh reinforcement for midline incisional hernia prevention: systematic review and updated meta-analysis of randomized controlled trials.

Hernia : the journal of hernias and abdominal wall surgery·2022

Same author

Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

A seasonal pattern in the onset of polymyalgia rheumatica and giant cell arteritis? A systematic review and meta-analysis.

Seminars in arthritis and rheumatism·2020

Same author

Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.

European journal of cancer (Oxford, England : 1990)·2020

Area of Science:

Oncology
Pharmacology
Biochemistry

Background:

Methotrexate resistance in cancer is a significant clinical challenge.
Common resistance mechanisms include dihydrofolate reductase gene amplification and impaired drug transport.
Existing strategies for overcoming resistance are limited.

Purpose of the Study:

To describe strategies for eradicating methotrexate-resistant cells.
To explore novel therapeutic approaches based on understanding resistance mechanisms.
To evaluate the potential of prodrugs and second-generation antifolates.

Main Methods:

Analysis of established mechanisms of methotrexate resistance in experimental and clinical settings.
Conceptual development of prodrugs targeting critical folate enzymes.

Related Experiment Videos

Evaluation of second-generation antifolates, such as trimetrexate, against resistant cell lines.

Main Results:

Identified dihydrofolate reductase gene amplification and impaired transport as key resistance mechanisms.
Proposed the development of prodrugs selectively activated by dihydrofolate reductase.
Second-generation antifolates demonstrate efficacy against methotrexate transport-resistant cells.

Conclusions:

Targeted strategies can overcome methotrexate resistance.
Prodrug development offers a promising avenue for novel antifolate therapies.
Second-generation antifolates like trimetrexate show clinical potential in treating resistant cancers.